The use of Karnofsky Performance Status (KPS) as a predictor of 3 month post discharge mortality in cirrhotic patients

Muhammad Ali Khalid, Inamullah Khan Achakzai, Shoaib Ahmed Khan, Zain Majid, Farina M Hanif, Javed Iqbal, Syed Mudassir Laeeq, Nasir Hassan Luck

Department of Hepatogastroenterology, Sindh Institute of Urology and Transplantation, (SIUT) Karachi, Pakistan

ABSTRACT

Aim: Is Karnofsky Performance Status (KPS) a predictor of 3 month post discharge mortality in cirrhotic patients?

Background: Cirrhotic patients often experience an abrupt decline in their health, which often leads to frequent hospitalization and can cause morbidity and mortality. Various models are currently used to predict mortality in cirrhotics however these have their limitations. The Karnofsky Performance Status (KPS) being one of the oldest performance status scales, is a health care provider–administered assessment that has been validated to predict mortality across the elderly and in the chronic disease populations.

Methods: We used the KPS performance status scale to envisage short-term mortality in cirrhotic and HCC patients who survive to be discharged from hospital.

Results: Our study showed that KPS one week post-discharge, child pugh score, hospital stay, international normalized ratio, serum albumin, total bilirubin and serum creatinine showed statistical significance on univariate analysis. On multivariate analysis, KPS was found to be statistical significant predictor of 3-month mortality.

Conclusion: Hence KPS can be utilized to identify cirrhotic patients at risk of 3-month post discharge mortality.

Keywords: Karnofsky Performance Status (KPS), Cirrhosis, 3 months mortality

Introduction

Hospitalization is a marker of poor outcomes including readmission and death. Patients with cirrhosis experience abrupt deterioration in their health that leads to repeated hospitalizations along with increased morbidity and mortality (1-3). Currently, the models used to predict mortality in cirrhotics are liver-specific and kidney-specific prognostic indicators such as the Model for End-Stage Liver Disease (MELD) score (4). However the MELD score has several limitations (5-7) one of them being its lack of ability to account for an individual’s performance status.

It is now a well-known fact that performance status and the linked concept of infirmity are strong predictors of adverse outcomes in patient populations (8-14) including cirrhosis (5-18) and it often outperforming established prognostic markers (19-20).

The Karnofsky Performance Status (KPS) is a health care provider–administered assessment that takes 1-2 minutes to assign a patient to one of the 10 categories (ranging from 0 [dead] to 100 [normal activity, no evidence of disease]). It is one of the oldest performance status scales (21) and has been validated to predict mortality across elderly and chronic disease populations (22-24). Orman et al identifying the KPS, independent of the liver function, as a predictor of liver transplant waiting list mortality (16). Thus KPS has been shown to be an important, user-friendly screening modality for an additional general risk stratification that can be readily administered in any clinical setting. In addition to being practical and easy to use, the validity and reliability of the KPS are well established (24-26).
Therefore the need to establish a practical prognostic model that could identify those at the highest risk of 3-months mortality lead us to validate the KPS as a prognostic predictor in our patient populations (those with cirrhosis and hepatocellular carcinoma). Since this would assist us in selecting patients who need a more intensive follow-up and consideration of early liver transplant when available. Furthermore, an assessment of the probability of survival could help us update the type of palliative support that is provided to patients.

**Methods**

Cirrhotic patients of either gender were prospectively enrolled non-electively in this study conducted at the Department of Hepatogastroenterology, Sindh Institute of Urology and Transplantation (SIUT), Karachi, Pakistan, a large tertiary care centre located in Pakistan’s largest city Karachi. These patients were followed for 3 months throughout their hospitalization or after discharge by using systematic phone calls, during outpatient visits and interviewed to evaluate for outcomes either within the hospital or elsewhere (1,27)

Patients were recruited from June 2016 until July 2017. A diagnosis of cirrhosis was established by endoscopic or radiological evidence of portal hypertension or cirrhosis, compatible biopsy findings, and/or signs of hepatic decompensation, including hepatic encephalopathy (HE), jaundice, variceal bleeding, and ascites. Patients who failed to give informed consent, those who were transplanted during hospitalization and those with metastatic cancer (excluding Hepatocellular Carcinoma), human immunodeficiency virus, or inability to obtain KPS assessment at 1 week after hospital discharge were excluded.

Data were collected regarding patient demographics, liver disease etiology and severity (MELD and Child-Pugh scores), admission variables (admission indication, cirrhosis complications and organ failures occurring during hospitalization, length of stay), and discharge variables (laboratory results, medications). At 1 week post discharge, the research assistant assessed the patient’s KPS using questions directed to the patient and the caregiver in a telephonic interview. The KPS score was categorized into low (score 10-40), intermediate (50-70), and high (80-100) (16). Subjects were followed for 3 months post discharge systematically to evaluate health outcomes. The collected data were entered into SPSS (version 20.0) and analyzed by the researcher. Mean and standard deviation were calculated for continuous variables. Frequency and percentages were calculated for categorical variables. Models for the prediction of 3-month mortality were based on variables measured at baseline, during the index stay, on the date of discharge from the index admission, and KPS at 1 week post discharge. A p value ≤ 0.05 was considered significant.

**Results**

The total number of patients enrolled were 108 out of which 64.8% were predominantly males. The mean age noted was 42.83 years. Most patients fell in CTP class B (42.6%). Hepatitis B virus (HBV) related and Hepatitis D related CLD was seen in 17 (15.8 %) and in 1 (0.92 %) patients respectively. Twenty six (24.07 %) patients had HCC due to unknown cause. (See in Table 1).

Hepatocellular carcinoma (HCC) was present in 50 (46.3 %) patients. Among these patients, 9 (18%) patients had a prior history of HBV infection while the remaining had HCV related CLD. Trans arterial chemoembolization (TACE) was performed in 41 (82 %) patients with tumor recurrence being documented in 8 (19.5 %) of these patients.

A 1 week hospital stay was noted in majority of patients i.e., 88 patients (81.5 %) while the rest had a stay more than 2 weeks. According to KPS scoring, 49 (45.4 %) patients fall into intermediate performance group, followed by 36 (33.33 %) patients in high and 23 (21.3 %) patients in low performance group.

The three month post discharge mortality was documented in 44 (40.7 %) patients. The mortality rates for the low, intermediate, and high performance status groups were 95.65 % (22/23), 38.7 % (19/49), and 8.3 % (3/36), respectively.

KPS one week post-discharge (p=0.00), Child class score (p=0.00), hospital stay (p=0.005), international normalized ratio (p=0.00), serum albumin (p=0.000), total bilirubin (p=0.000), serum creatinine (p=0.009) showed statistical significance on univariate analysis.
On multivariate analysis, KPS (p=0.016) was found to be a statistical significant predictor of 3-month mortality. After stratifying data for the presence of HCC, univariate analysis had statistical significance with KPS one week post-discharge (p=0.00), Child class score (p=0.04), international normalized ratio (p=0.04) and serum albumin (p=0.000). On multivariate analysis, KPS (p=0.34) and serum albumin (p=0.016) were found to be a statistical significant predictor of 3-month mortality after discharge.

**Discussion**

In cirrhotic patients, accurate prognostication is indispensable because it guides us to prescribe the type and decide about the frequency of clinical care and helps us inform patients and their families about their possible outcomes. To our information, this is the first single center prospective study done in Pakistan using a performance status scale (KPS) to envisage short-term mortality in cirrhotic and HCC patients who survive to be discharged from hospital.

Our study is in accord with Tandon et al (28) who also documented similar finding in their study by using the same KAM model. This also extends the results of the recently done retrospective study done by Orman et al.16 and Tapper et al., (15) identified activities of daily living score done at hospital admission as a predictor of either 90-day in-hospital or post discharge mortality.

In routine clinical practice the addition of the KPS has been found to be highly reproducible and predictive in cirrhosis seen during outpatient visits, even when compared to the other more lengthy performance status evaluations such as the Fried Frailty Scale and the Short Physical Performance Battery (18).

As estimated of a hospitalized population, the scores in our cohort were significantly worse than those noted in the transplant waiting list study by Orman et al. (16) At 1 week post–hospital discharge, 33% of patients were in the high performance status range at 1 week post–hospital discharge. Forty-five percent had intermediate scores, reflecting incapability to work and a requirement of support for personal needs. Only 21% of patients had a low KPS score, consistent with lack of ability to care for oneself and the need for the equivalent of institutional care. The proper provision of support in this area may be a key factor in reducing the astonishing rates of rehospitalization in this population (1). The poor performance status of this group supports the significance of a multidisciplinary approach prior to discharge these patients. We have also seen similar findings in HCC group i.e. those who had low KPS scores at 1 week, they have a high 3 months mortality in our follow up.

A low 1 week post discharge KPS score was predicted by child class score, hospital stay, international normalized ratio (INR), serum albumin, total bilirubin,

| Variable | p-value |
|----------|---------|
| Age, years, mean±SD (range) | 0.38 |
| Gender, n (%) | 0.31 |
| Child Class, n (%) | <0.0001 |
| HCC presence, n (%) | 0.23 |
| 1 week Hospital stay, n (%) | 0.005 |
| KPS one week after discharge, n (%) | 0.00 |
| international normalized ratio, mean±SD | <0.0001 |
| Albumin, mean±SD | <0.0001 |
| Total bilirubin, mean±SD | <0.0001 |
| Alanine aminotransferase, mean±SD | 0.12 |
| Alkaline Phosphatase, mean±SD | 0.32 |
| Gamma- Glutamyl transferase, mean±SD | 0.43 |
| Serum Sodium, mean±SD | 0.93 |
| Serum Creatinine, mean±SD | 0.009 |
serum creatinine. A more meticulous assessment of potentially adjustable factors that impact performance status in hospitalized patients will be an imperative area of focus for follow-on studies. As has been eminent in studies of functional decline occurring during hospitalization, it is expected that potentially amendable factors such as in-hospital nutritional intake and in hospital mobilization may also play a vital role in predicting discharge performance status (29).

The independent prognostic assessment of performance status highlights the need to incorporate palliative care principles (advanced care planning, goals of care discussions, palliative symptom management) in the management of the bulk of our patients being discharged from hospital. Patients at high peril of death should be assessed for a care plan using integrated palliative management strategies and, if possible, considered for live donor liver transplantation.

In our study post discharge three months mortality was documented in 44 (40.7 %) patients. The mortality rates for the low, intermediate, and high performance status groups were 95.65 %, 38.7 % and 8.3 %, respectively. Furthermore, high risk patients may benefit from earlier follow-up and escalation of their active disease management post discharge (30).

The limitations of our study were that we did not assess the KPS on the day of hospital admission or on the day of discharge and as a result we were not capable to depict a change in the performance status. Secondly it was beyond the extent of our study to evaluate several factors previously related with post hospitalization functional decline, including the prehospitalization functional reserve or the nutrition and mobilization therapy provided in hospital. This can be the focus of follow-on studies. Lastly it was a single centre study and further studies will be needed to validate this association.

Almost 41% of cirrhotic patients who survive until discharge die within 3 months after hospitalization. These patients can be identified using the KPS based performance status score. This easy-to-use measurement is strongly and independently linked with an increased hazard of mortality and could be adopted in practice to lead post discharge early interventions, as well as the integrated provision of vigorous and palliative management strategies.

Conflict of interests

The authors declare that they have no conflict of interest.

References

1. Bajaj JS, Reddy KR, Tandon P, Wong F, Kamath PS, Garcia-Tsao G, et al. The 3-month readmission rate remains unacceptably high in a large North American cohort of patients with cirrhosis. Hepatology 2016;64:200-8.
2. Moreau R, Jalan R, Gines P, Pavesi M, Angeli P, Cordoba J, et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology 2013;144:1426-37.
3. Cordoba J, Ventura-Cots M, Simon-Talero M, Amoros A, Pavesi M, Vilstrup H, et al. Characteristics, risk factors, and mortality of cirrhotic patients hospitalized for hepatic encephalopathy with and without acute-on-chronic liver failure (ACLF). J Hepatol 2014;60:275-81.
4. Kamath PS, Wiesner RH, Malinchoc M, Kremers W, TherneauTM, Kosberg CL, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001;33:464-70.
5. Huo TI, Lee SD, Lin HC. Selecting an optimal prognostic system for liver cirrhosis: the model for end-stage liver disease and beyond. Liver Int 2008;28:606-13.
6. Bambha KM, Bambha SW. Inequities of the Model for End-Stage Liver Disease: an examination of current components and future additions. Curr Opin Organ Transplant 2008;13:227-33.
7. Bambha SW, Bambha KM. MELD-based liver allocation: who is underserved? Semin Liver Dis 2006;26:211-20.
8. Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gott diener J, et al. Cardiovascular Health Study Collaborative Research Group. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 2001;56:M146-56.
9. Rockwood K, Howlett SE, MacKnight C, Beattie BL, Bergman H, Hebert R, et al. Prevalence, attributes, and outcomes of fitness and frailty in community-dwelling older adults: report from the Canadian Study of Health and Aging. J Gerontol A Biol Sci Med Sci 2004;59:1310-7.
10. Afifalo J, Karunanithnan S, Eisenberg MJ, Alexander KP, Bergman H. Role of frailty in patients with cardiovascular disease. Am J Cardiol 2009;103:1616-21.
11. Uchmanowicz I, Loboz-Rudnicka M, Zselag P, Jankowska- Polanska B, Loboz-Grudzien K. Frailty in heart failure. Curr Heart Fail Rep 2014;11:266-73.
12. Johansen KL, Chertow GM, Jin C, Kutner NG. Significance of frailty among dialysis patients. J Am Soc Nephrol 2007;18:2960-7.
13. Park SK, Richardson CR, Holleman RG, Larson JL. Frailty in people with COPD, using the National Health and Nutrition Evaluation Survey dataset (2003-2006). Heart Lung 2013;42:163-70.
14. Kahlon S, Pederson J, Majumdar SR, Belga S, Lau D, Fradette M, et al. Association between frailty and 30-day outcomes after discharge from hospital. CMAJ 2015;187:799-804.

15. Tapper EB, Finkelstein D, Mittleman MA, Piatkowski G, Lai M. Standard assessments of frailty are validated predictors of mortality in hospitalized patients with cirrhosis. Hepatology 2015;62:584-90.

16. Orman ES, Ghabril M, Chalasani N. Poor Performance Status Is Associated With Increased Mortality in Patients With Cirrhosis. Clin Gastroenterol Hepatol. 2016 ;14:1189-95.

17. Lai JC, Feng S, Terrault NA, Lizaola B, Hayssen H, Covinsky K. Frailty predicts waitlist mortality in liver transplant candidates Am J Transplant 2014;14:1870-9.

18. Tandon P, Tangri N, Thomas L, Zenith L, Shaikh T, Carbonneau M, et al. A Rapid Bedside Screen to Predict Unplanned Hospitalization and Death in Outpatients With Cirrhosis: A Prospective Evaluation of the Clinical Frailty Scale. Am J Gastroenterol 2016;111:1759-67.

19. Mitnitski AB, Graham JE, Mogilner AJ, Rockwood K. Frailty, fitness and late-life mortality in relation to chronological and biological age. BMC Geriatr 2002;2:1.

20. Zimmermann C, Burman D, Bandukwala S, Seccareccia D, Kaya E, Bryson J, et al. Nurse and physician inter-rater agreement of three performance status measures in palliative care outpatients. Support Care Cancer 2010;18:609-16.

21. Karnofsky DA, Burchenal JH. The clinical evaluation of chemotherapeutic agents in cancer. In: MacLeod CM, ed. Evaluatio of Chemotherapeutic Agents in Cancer. New York: Columbia University Press;1949:191-205.

22. van Diepen M, Schrojen MA, Dekkers OM, Rotmans JI, Krediet RT, Boeschoten EW, et al. Predicting mortality in patients with diabetes starting dialysis. PLoS One 2014;9: e89744.

23. Brezinski D, Stone PH, Muller JE, Tofler GH, Davis V, Parker C, et al. Prognostic significance of the Karnofsky Performance Status score in patients with acute myocardial infarction: comparison with the left ventricular ejection fraction and the exercise treadmill test performance. The MILIS Study Group. Am Heart J 1991;121:1374-81.

24. Crooks V, Waller S, Smith T, Hahn TJ. The use of the Karnofsky Performance Scale in determining outcomes and risk in geriatric outpatients. J Gerontol 1991;46:M139-44.

25. Schag CC, Heinrich RL, Ganz PA. Karnofsky performance status revisited: reliability, validity, and guidelines. J Clin Oncol 1984;2:187-93.

26. Mor V, Laliberte L, Morris JN, Wiemann M. The Karnofsky Performance Status scale. An examination of its reliability and validity in a research setting. Cancer 1984;53:2002-7.

27. Bajaj JS, O’Leary JG, Reddy KR, Wong F, Olson JC, Subramanian RM, et al. Second infections independently increase mortality in hospitalized patients with cirrhosis: the North American Consortium for the Study of End-Stage Liver Disease (NACSELD) experience. Hepatology 2012;56:2328-35.

28. Tandon P, Reddy KR, O’Leary JG, Garcia-Tsao G, Abraldes JG, Wong F, Biggins SW, Maliakkal B, Fallon MB, Subramanian RM, Thuluvath P, Kamath PS, Thacker LR, Bajaj JS; North American Consortium for the Study of End-Stage Liver Disease. A Karnofsky performance status-based score predicts death after hospital discharge in patients with cirrhosis. Hepatology 2017;65:217-24.

29. Zisberg A, Shadmi E, Gur-Yaish N, Tonkikh O, Sinoff G. Hospital-associated functional decline: the role of hospitalization processes beyond individual risk factors. J Am Geriatr Soc 2015;63:55-62.

30. Kanwal F, Asch SM, Kramer JR, Cao Y, Asrani S, El-Serag HB. Early outpatient follow-up and 30-day outcomes in patients hospitalized with cirrhosis. Hepatology 2016;64:569-81.